Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase
Latest Information Update: 26 Apr 2024
At a glance
- Drugs Decitabine (Primary) ; Fedratinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Adverse reactions
- 19 Apr 2024 Status changed from recruiting to discontinued.
- 02 Sep 2022 New trial record